DRDO invites expression of interest for bulk production of Covid drug 2-DG


The Defence Research and Development Organisation (DRDO), which developed 2 -Deoxy-D-Glucose (2-DG), a drug used for the treatment of COVID-19 patients, has called for Express of Interest (EOI) to transfer the technology to Indian pharmaceutical industries for production.

The 2-DG is developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’ Laboratories.

The third phase trials of 2-DG began in January, while the phase trials were conducted over three month period between June and September last year and involved 110 patients.

The DCGI had granted permission in May last year to Dr Reddy’s Laboratories for conducting a clinical trial of 2 DG for “acute treatment of moderate to severe Covid-19 patients.”

The government has recently launched 2-DG as an anti -Covid-19 therapeutic application of the drug 2-Deoxy-D-glucose (2-DG).

Patients treated with 2-DG have shown negative RT-PCR in COVID-19 patients.

Recommended For You